Tag - GNCA

Genocea Biosciences

SVB Leerink starts Genocea Biosciences at OP; PT $7

SVB Leerink launched coverage of Genocea Biosciences (NASDAQ:GNCA) with an “outperform” rating and price target of $7. The stock closed at $2.24 on Nov. 14. “Our positive view is based on the promise of Genocea’s ATLAS...

Genocea Biosciences

Stifel ups Genocea Biosciences PT to $18 from $5

Stifel hiked its price target for Genocea Biosciences (NASDAQ:GNCA) to $18 from $5 after raising the probability of success to 20% from 15% for Phase 1 efficacy data of the company’s cancer vaccine, GEN-009. The stock...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.